The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katunina E.A.

Pirogov Russian National Research Medical University (Pirogovsky University);
Federal Center for Brain and Neurotechnology

Parusova A.V.

Federal Center for Brain and Neurotechnology

Golovanova I.V.

Pirogov City Clinical Hospital No. 1

Zavadtseva N.V.

Pirogov City Clinical Hospital No. 1

Cognitive impairment in patients with Parkinson’s disease

Authors:

Katunina E.A., Parusova A.V., Golovanova I.V., Zavadtseva N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(11): 81‑90

DOI: 10.17116/jnevro202412411181

Views: 634

Downloaded: 4

Buy for 300₽
Contact the author
Table of contents

COGNITIVE IMPAIRMENT IN PATIENTS WITH PARKINSON’S DISEASE
COGNITIVE IMPAIRMENT IN PATIENTS WITH PARKINSON’S DISEASE

To cite this article:

Katunina EA, Parusova AV, Golovanova IV, Zavadtseva NV. Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(11):81‑90. (In Russ.)
https://doi.org/10.17116/jnevro202412411181

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Tremor-dominant form of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):28-35
Nocturia in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):48-54
Asso­ciations of serum neuromarkers with clinical features of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):145-152
Prevalence of cognitive impairment in older adults in the Russian Fede­ration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11
Respiratory-syncitial virus: biology, gene­tic dive­rsity and perspective control preparations. Mole­cular Gene­tics, Microbiology and Viro­logy. 2024;(1):16-24
Gene­tic factors in dege­nerative disc disease. Burdenko's Journal of Neurosurgery. 2024;(2):112-118
Pathogenetic, clinical-diagnostic and therapeutic aspe­cts of premenstrual syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):37-42
Morphological features of vaso­proliferative tumor of the retina. Russian Journal of Archive of Pathology. 2024;(2):42-50
Rela­pse of primary mediastinal B-cell lymphoma with isolated central nervous system invo­lvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Onco­logy. 2024;(2):39-45
Clinical and morphological asse­ssment of patients with adenomyosis: own data. Russian Journal of Human Reproduction. 2024;(2):130-135

Parkinson’s disease manifests itself in both motor and non-motor symptoms, that occupies an important place among non-motor symptoms. The article provides an overview of the spectrum of cognitive disorders in this disease, examines their pathomorphological and neurotransmitter basis. Risk factors, diagnostic criteria, as well as complex therapy, including both neurotransmitter and neurotrophic drugs, methods of physical and cognitive rehabilitation, are discussed.

Keywords:

Parkinson’s disease
cognitive impairment
dementia
mild cognitive disorder
pathogenesis
therapy
neurotrophic therapy

Authors:

Katunina E.A.

Pirogov Russian National Research Medical University (Pirogovsky University);
Federal Center for Brain and Neurotechnology

Parusova A.V.

Federal Center for Brain and Neurotechnology

Golovanova I.V.

Pirogov City Clinical Hospital No. 1

Zavadtseva N.V.

Pirogov City Clinical Hospital No. 1

Received:

09.10.2024

Accepted:

14.10.2024

List of references:

  1. Katunina E, Titova N. The Epidemiology of Nonmotor Symptoms in Parkinson’s Disease (Cohort and Other Studies). International Review of Neurobiology. 2017;133:91-110.  https://doi.org/10.1016/bs.irn.2017.05.012
  2. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Movement Disorders. 2019;34(10):1464-1470. https://doi.org/10.1002/mds.27802
  3. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59(11):1708-1713. https://doi.org/10.1212/01.wnl.0000036610.36834.e0
  4. Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson’s disease: results of an Italian cohort study. Parkinsonism & Related Disorders. 2011;17(4):265-269.  https://doi.org/10.1016/j.parkreldis.2011.01.003
  5. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet. Neurology. 2012;11(8):697-707.  https://doi.org/10.1016/S1474-4422(12)70152-7
  6. Perez F, Helmer C, Foubert-Samier A, et al. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimer’s & Dementia. 2012;8(6):463-469.  https://doi.org/10.1016/j.jalz.2011.09.230
  7. Kim JW, Cheon SM, Park MJ, et al. Cognitive impairment in Parkinson’s disease without dementia: subtypes and influences of age. Journal of Clinical Neurology. 2009;5(3):133-138.  https://doi.org/10.3988/jcn.2009.5.3.133
  8. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). Journal of Neurology. 2008;255(2):255-264.  https://doi.org/10.1007/s00415-008-0720-2
  9. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Movement Disorders. 2005;20(10):1255-1263. https://doi.org/10.1002/mds.20527
  10. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(11):2958-2969. https://doi.org/10.1093/brain/awp245
  11. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;84(11):1258-1264. https://doi.org/10.1136/jnnp-2013-305277
  12. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837-844.  https://doi.org/10.1002/mds.21956
  13. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9(1):63-75.  https://doi.org/10.1016/j.jalz.2012.11.007
  14. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062-1069. https://doi.org/10.1212/WNL.0b013e3181f39d0e
  15. Broeders M, de Bie RM, Velseboer DC, et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2013;81(4):346-352.  https://doi.org/10.1212/WNL.0b013e31829c5c86
  16. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. Neurology. 2017;88(8):767-774.  https://doi.org/10.1212/WNL.0000000000003634
  17. Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: A meta-analysis. Movement Disorders. 2020;35(1):45-54.  https://doi.org/10.1002/mds.27902
  18. Lawson RA, Yarnall AJ, Duncan GW, et al. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2017;88(8):648-652.  https://doi.org/10.1136/jnnp-2016-315099
  19. Domellöf ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurologica Scandinavica. 2015;132(2):79-88.  https://doi.org/10.1111/ane.12375
  20. Roberts R, Knopman DS. Classification and epidemiology of MCI.. Clinics in Geriatric Medicine. 2013;29(4):753-772.  https://doi.org/10.1016/j.cger.2013.07.003
  21. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. Journal of the American Geriatrics Society. 2000;48(8):938-942.  https://doi.org/10.1111/j.1532-5415.2000.tb06891.x
  22. Schrag A, Siddiqui UF, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet. Neurology. 2017;16(1):66-75.  https://doi.org/10.1016/S1474-4422(16)30328-3
  23. Jones JD, Kuhn TP, Szymkowicz SM. Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: Analysis of the PPMI cohort. Parkinsonism & Related Disorders. 2018;47:3-7.  https://doi.org/10.1016/j.parkreldis.2017.12.006
  24. Skorvanek M, Goldman JG, Jahanshahi M, et al. Global scales for cognitive screening in Parkinson’s disease: Critique and recommendations. Movement Disorders. 2018;33(2):208-218.  https://doi.org/10.1002/mds.27233
  25. Matteau E, Dupré N, Langlois M, et al. Mattis Dementia Rating Scale 2: screening for MCI and dementia. American Journal of Alzheimer’s Disease and Other Dementias. 2011;26(5):389-398.  https://doi.org/10.1177/1533317511412046
  26. Matteau E, Dupré N, Langlois M, et al. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. Journal of Geriatric Psychiatry and Neurology. 2012;25(2):100-106.  https://doi.org/10.1177/0891988712445086
  27. Bezdicek O, Michalec J, Nikolai T, et al. Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson’s disease and normative data. Dementia and Geriatric Cognitive Disorders. 2015;39(5-6):303-311.  https://doi.org/10.1159/000375365
  28. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717-1725. https://doi.org/10.1212/WNL.0b013e3181fc29c9
  29. Lucza T, Karádi K, Kállai J, et al. Screening Mild and Major Neurocognitive Disorders in Parkinson’s Disease. Behavioural neurology. 2015;2015:983606. https://doi.org/10.1155/2015/983606
  30. Bezdicek O, Majerova V, Novak M, et al. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington’s disease. Applied neuropsychology. Adult. 2013;20(1):33-40.  https://doi.org/10.1080/09084282.2012.670158
  31. Pagonabarraga J, Kulisevsky J, Llebaria G, et al. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Movement Disorders. 2008;23(7):998-1005. https://doi.org/10.1002/mds.22007
  32. Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, et al. Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Movement Disorders. 2013;28(10):1376-1383. https://doi.org/10.1002/mds.25568
  33. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Movement Disorders. 2012;27(3):349-356.  https://doi.org/10.1002/mds.24893
  34. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders. 2007;22(12):1689-1707. https://doi.org/10.1002/mds.21507
  35. Gonzalez-Latapi P, Bayram E, Litvan I, Marras C. Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral sciences. 2021;11(5):74.  https://doi.org/10.3390/bs11050074
  36. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers. 2021;7(1):47.  https://doi.org/10.1038/s41572-021-00280-3
  37. Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Movement Disorders. 2018;33(12):1857-1870. https://doi.org/10.1002/mds.27527
  38. Kasten M, Klein C. The many faces of alpha-synuclein mutations. Movement Disorders. 2013;28(6):697-701.  https://doi.org/10.1002/mds.25499
  39. Zhang Y, Sun QY, Zhao YW, et al. Effect of GBA Mutations on Phenotype of Parkinson’s Disease: A Study on Chinese Population and a Meta-Analysis. Parkinson’s disease. 2015;2015:916971. https://doi.org/10.1155/2015/916971
  40. Creese B, Bell E, Johar I, et al. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson’s disease and Lewy body dementias: Review and meta-analyses. American Journal of Medical Genetics. 2018;177(2):232-241.  https://doi.org/10.1002/ajmg.b.32549
  41. Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Annals of Neurology. 2016;80(5):674-685.  https://doi.org/10.1002/ana.24781
  42. Piredda R, Desmarais P, Masellis M, Gasca-Salas C. Cognitive and psychiatric symptoms in genetically determined Parkinson’s disease: a systematic review. European Journal of Neurology. 2020;27(2):229-234.  https://doi.org/10.1111/ene.14115
  43. Kasten M, Hartmann C, Hampf J, et al. Genotype-Phenotype Relations for the Parkinson’s Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Movement Disorders. 2018;33(5):730-741.  https://doi.org/10.1002/mds.27352
  44. Grünewald A, Kasten M, Ziegler A, Klein C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurology. 2013;70(9):1186-1191. https://doi.org/10.1001/jamaneurol.2013.488
  45. Liu R, Umbach DM, Peddada SD, et al. Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. Neurology. 2015;84(21):2107-2115. https://doi.org/10.1212/WNL.0000000000001609
  46. Munro CA, Winicki JM, Schretlen DJ, et al. Sex differences in cognition in healthy elderly individuals. Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition. 2012;19(6):759-768.  https://doi.org/10.1080/13825585.2012.690366
  47. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism and Related Disorders. 2014;20(1):99-105.  https://doi.org/10.1016/j.parkreldis.2013.09.025
  48. Guo Y, Xu W, Liu FT, et al. Modifiable risk factors for cognitive impairment in Parkinson’s disease: A systematic review and meta-analysis of prospective cohort studies. Movement Disorders. 2019;34(6):876-883.  https://doi.org/10.1002/mds.27665
  49. Nicoletti A, Luca A, Baschi R, et al. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study. Journal of Neurology. 2021;268(2):549-558.  https://doi.org/10.1007/s00415-020-10189-8
  50. Ashraghi MR, Pagano G, Polychronis S, et al. Parkinson’s Disease, Diabetes and Cognitive Impairment. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery. 2016;10(1):11-21.  https://doi.org/10.2174/1872214810999160628105549
  51. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology. 2000;54(10):1916-1921. https://doi.org/10.1212/wnl.54.10.1916
  52. Chahine LM, Dos Santos C, Fullard M, et al. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson’s disease. European Journal of Neurology. 2019;26(2):246-e18.  https://doi.org/10.1111/ene.13797
  53. Erten-Lyons D, Woltjer R, Kaye J, et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology. 2013;81(11):977-983.  https://doi.org/10.1212/WNL.0b013e3182a43e45
  54. Kozac VV. Determining the risk of dementia in Parkinson’s disease: possibilities and perspectives. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(6):137-143. (In Russ.). https://doi.org/10.17116/jnevro2019119061137
  55. David FJ, Robichaud JA, Leurgans SE, et al. Exercise improves cognition in Parkinson’s disease: The PRET-PD randomized, clinical trial. Movement Disorders. 2015;30(12):1657-1663. https://doi.org/10.1002/mds.26291
  56. Picelli A, Varalta V, Melotti C, et al. Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson’s disease: a pilot, single-blind, randomizedtrial. Functional Neurology. 2016;31(1):25-31.  https://doi.org/10.11138/fneur/2016.31.1.025
  57. Cho BH, Choi SM, Kim JT, Kim BC. Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson’s disease. Parkinsonism and Related Disorders. 2018;50:42-47.  https://doi.org/10.1016/j.parkreldis.2018.02.016
  58. Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? Journal of Geriatric Psychiatry and Neurology. 2014;27(4):276-281.  https://doi.org/10.1177/0891988714532015
  59. Galtier I, Nieto A, Lorenzo JN, Barroso J. Subjective cognitive decline and progression to dementia in Parkinson’s disease: a long-term follow-up study. Journal of Neurology. 2019;266(3):745-754.  https://doi.org/10.1007/s00415-019-09197-0
  60. Klinicheskie rekomendatsii. Bolezn’ Parkinsona, vtorichnyj parkinsonizm i drugie zabolevanija, projavljajushhiesja sindromom parkinsonizma. 2021. (In Russ.). Accessed September 26, 2024. https://disuria.ru/_ld/12/1253_kr21G20G23MZ.pdf
  61. Sasikumar S, Strafella AP. Imaging Mild Cognitive Impairment and Dementia in Parkinson’s Disease. Frontiers in Neurology. 2020;11:47.  https://doi.org/10.3389/fneur.2020.00047
  62. Westbrook A, van den Bosch R, Määttä JI, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020;367(6484):1362-1366. https://doi.org/10.1126/science.aaz5891
  63. Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research. 2004;318(1):121-134.  https://doi.org/10.1007/s00441-004-0956-9
  64. Titova N, Qamar MA, Chaudhuri KR. Biomarkers of Parkinson’s Disease: An Introduction. International review of Neurobiology. 2017;132:183-196.  https://doi.org/10.1016/bs.irn.2017.03.003
  65. Buddhala C, Loftin SK, Kuley BM, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Annals of Clinical and Translational Neurology. 2015;2(10):949-959.  https://doi.org/10.1002/acn3.246
  66. Ballinger EC, Ananth M, Talmage DA, Role LW. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016;91(6):1199-1218. https://doi.org/10.1016/j.neuron.2016.09.006
  67. Bohnen NI, Albin RL, Müller ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurology. 2015;72(2):194-200.  https://doi.org/10.1001/jamaneurol.2014.2757
  68. Pereira JB, Hall S, Jalakas M, et al. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease. Neurobiology of Disease. 2020;139:104831. https://doi.org/10.1016/j.nbd.2020.104831
  69. Smith C, Malek N, Grosset K, et al. Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies. Journal of Neurology, Neurosurgery, and Psychiatry. 2019;90(11):1234-1243. https://doi.org/10.1136/jnnp-2019-321111
  70. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14(4):535-562.  https://doi.org/10.1016/j.jalz.2018.02.018
  71. Winer JR, Maass A, Pressman P, et al. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease. JAMA Neurology. 2018;75(2):227-235.  https://doi.org/10.1001/jamaneurol.2017.3713
  72. Reimand J, Collij L, Scheltens P, et al; Alzheimer’s Disease Neuroimaging Initiative. Association of amyloid-β CSF/PET discordance and tau load 5 years later. Neurology. 2020;95(19):e2648-e2657. https://doi.org/10.1212/WNL.0000000000010739
  73. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. New England Journal of Medicine, NEJM. 2004;351(24):2509-2518. https://doi.org/10.1056/NEJMoa041470
  74. Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Movement Disorders. 2015;30(7):912-918.  https://doi.org/10.1002/mds.26236
  75. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Movement Disorders. 2012;27(10):1230-1238. https://doi.org/10.1002/mds.25098
  76. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Movement Disorders. 2019;34(2):180-198.  https://doi.org/10.1002/mds.27602
  77. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet. Neurology. 2009;8(7):613-618.  https://doi.org/10.1016/S1474-4422(09)70146-2
  78. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet. Neurology. 2010;9(10):969-977.  https://doi.org/10.1016/S1474-4422(10)70194-0
  79. Stubendorff K, Larsson V, Ballard C, et al. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158. https://doi.org/10.1136/bmjopen-2014-005158
  80. Gauthier S, Proaño JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders. 2015;39(5-6):332-347.  https://doi.org/10.1159/000377672
  81. Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2019;2019(11):CD008900. https://doi.org/10.1002/14651858.CD008900.pub3
  82. Alvarez XA, Alvarez I, Iglesias O, et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. International Journal of Neuropsychopharmacology. 2016;19(6):pyw024. https://doi.org/10.1093/ijnp/pyw024
  83. Damulin IV, Mkhitaryan EA, Koberskaya NN. Cerebrolysin for the treatment of mild cognitive impairment of vascular origin. Terapevticheskij Arhiv. 2007;79(6):65-69. (In Russ.).
  84. Mishchenko VN. K voprosu ob effektivnosti preparata Cerebrolizin u bol’nyh s «nemymi» infarktami mozga. Mezhdunarodnyj Nevrologicheskij Zhurnal. 2015;3(73):15-20. (In Russ.).
  85. Castrén E, Võikar V, Rantamäki T. Role of neurotrophic factors in depression. Current Opinion in Pharmacology. 2007;7(1):18-21.  https://doi.org/10.1016/j.coph.2006.08.009
  86. Zujkova NL, Israeljan AJu, Gushanskaja EV, Medvedev VE. Cerebrolysin in the treatment of depressions. Psihiatrija i Psihofarmakoterapija. 2013;1:41- 46. (In Russ.).
  87. Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology. 2011;18(1):59-68.  https://doi.org/10.1111/j.1468-1331.2010.03092.x
  88. Alvarez XA, Cacabelos R, Sampedro C, et al. Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Current Alzheimer Research. 2011;8(5):583-591.  https://doi.org/10.2174/156720511796391863
  89. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159.  https://doi.org/10.1161/STROKEAHA.115.009416
  90. Levin OS, Voznyuk IA, Illarioshkin SN, et al. Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Expert. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):121-130. (In Russ.). https://doi.org/10.17116/jnevro2023123091121
  91. Lawrence BJ, Gasson N, Bucks RS, et al. Cognitive Training and Noninvasive Brain Stimulation for Cognition in Parkinson’s Disease: A Meta-analysis. Neurorehabilitation and Neural Repair. 2017;31(7):597-608.  https://doi.org/10.1177/1545968317712468
  92. Orgeta V, McDonald KR, Poliakoff E, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease. Cochrane Database of Systematic Reviews. 2020;2(2):CD011961. https://doi.org/10.1002/14651858.CD011961.pub2
  93. da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018;13(2):e0193113. https://doi.org/10.1371/journal.pone.0193113
  94. Dinkelbach L, Brambilla M, Manenti R, Brem AK. Non-invasive brain stimulation in Parkinson’s disease: Exploiting crossroads of cognition and mood. Neurosci Biobehavioral Reviews. 2017;75:407-418.  https://doi.org/10.1016/j.neubiorev.2017.01.021
  95. Package of interventions for rehabilitation. Module 3. Neurological conditions. Geneva: World Health Organization; 2023. Accessed September 26, 2024. https://www.who.int/publications/i/item/9789240071131

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.